This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62
Yuan F et al. (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93: 14765–14770
Segers J et al. (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature. Cancer Lett 244: 129–135
Tong RT et al. (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731–3736
Winkler F et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553–563
Acknowledgements
The synopsis was written by Rohit R Sharma and Ralph R Weichselbaum.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RR Sharma declared he has no competing interests. RR Weichselbaum has declared stock, consulting fees and research agreement with GenVec.
Rights and permissions
About this article
Cite this article
Sharma, R., Weichselbaum, R. Angiogenesis inhibition: the next frontier in multimodal therapy for glioblastoma multiforme. Nat Rev Clin Oncol 4, 454–455 (2007). https://doi.org/10.1038/ncponc0879
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0879